Attached files

file filename
EX-99.1 - PRESS RELEASE - FENNEC PHARMACEUTICALS INC.v331508_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) January 7, 2013

 

Adherex Technologies Inc.
(Exact Name of Registrant as Specified in Its
Charter)

 

Canada   001-32295   20-0442384

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709

(Address of Principal Executive Offices) (Zip Code)

 

919-636-4530

(Registrant’s Telephone Number, Including Area Code)

 

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 
 

 

Item 8.01 Other Events

 

On January 7, 2013, Adherex Technologies, Inc. (the “Company”) issued a press release to announce that the Company had completed enrollment and maintained its TSX listing status. The full text of the press release is furnished as Exhibit 99.1.

 

 

Item 9.01 Financial Statements and Exhibits

 

Exhibits

 

99.1 Press Release issued by Adherex Technologies, Inc. dated January 7, 2103.

 

 

 

 

 
 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: January 7, 2013 Adherex Technologies Inc.  
       
  By: /s/ Robert Andrade  
    Chief Financial Officer